Roberts Glore & Co. Inc. IL Buys Shares of 3,849 Medpace Holdings, Inc. $MEDP

Posted by George Bondi on Aug 26th, 2026

Roberts Glore & Co. Inc. IL purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,849 shares of the company’s stock, valued at approximately $2,039,000.

Several other hedge funds have also recently modified their holdings of the stock. Johnson Financial Group Inc. acquired a new position in Medpace in the 2nd quarter valued at $27,000. Elyxium Wealth LLC acquired a new stake in shares of Medpace in the 4th quarter worth $30,000. Jones Financial Companies Lllp acquired a new stake in shares of Medpace in the 2nd quarter worth $30,000. Allied Private Wealth LLC purchased a new stake in shares of Medpace in the second quarter valued at about $31,000. Finally, Kilter Group LLC purchased a new stake in shares of Medpace in the second quarter valued at about $31,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently issued reports on MEDP shares. Leerink Partners set a $620.00 price target on shares of Medpace in a report on Thursday, July 23rd. Mizuho lifted their price objective on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Truist Financial boosted their target price on Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. BMO Capital Markets increased their target price on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research note on Friday, July 24th. Finally, Robert W. Baird raised their price target on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat, Medpace currently has an average rating of “Hold” and an average price target of $584.18.

Get Our Latest Report on Medpace

Insider Transactions at Medpace

In related news, CEO August J. Troendle sold 27,174 shares of Medpace stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $618.79, for a total transaction of $16,814,999.46. Following the completion of the transaction, the chief executive officer directly owned 561,195 shares of the company’s stock, valued at approximately $347,261,854.05. The trade was a 4.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Fred B. Davenport, Jr. sold 7,283 shares of the business’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $606.15, for a total value of $4,414,590.45. Following the sale, the director owned 3,798 shares in the company, valued at approximately $2,302,157.70. The trade was a 65.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 141,639 shares of company stock worth $83,824,038 over the last ninety days. 20.50% of the stock is currently owned by corporate insiders.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

Positive Sentiment: Medpace’s latest quarterly results were strong: earnings of $4.25 per share exceeded the $3.98 consensus estimate, while revenue rose 17.2% year over year to $707.33 million, ahead of expectations. Management’s fiscal 2026 EPS guidance is $17.25–$17.95. Institutional ownership is also high at approximately 78%, with several large investors adding positions.
Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day days-to-cover ratio. Because the figures show no measurable short position, they provide little indication of near-term buying or selling pressure.
Neutral Sentiment: Analyst sentiment remains mixed. The consensus rating is “Hold,” with an average price target of $584.18, below recent trading levels. BMO Capital Markets raised its target to $600 while maintaining a market-perform rating, and Weiss Ratings upgraded the stock to “Buy.”
Negative Sentiment: Multiple company insiders recently sold shares. CEO August J. Troendle sold 13,995 shares for approximately $8.74 million on August 21 and another 1,983 shares for about $1.23 million on August 24. CFO Kevin Brady sold 3,400 shares worth roughly $2.13 million, reducing his ownership by 20.95%. Additional director sales were also reported. Although executives retain significant holdings, the concentration of selling can weigh on investor confidence.

Medpace Trading Down 1.0%

Shares of MEDP opened at $614.06 on Wednesday. The firm’s 50-day moving average is $556.26 and its two-hundred day moving average is $492.77. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The firm has a market capitalization of $17.14 billion, a P/E ratio of 35.99, a PEG ratio of 2.77 and a beta of 1.15.

Medpace (NASDAQ:MEDP – Get Free Report) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same period last year, the company posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Medpace Profile

(Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.